Homozygous Familial Hypercholesterolemia Rare Disease

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Subject wise Global Events

Homozygous Familial Hypercholesterolemia Rare Disease

The patients with severe HoFH illustrate the natural history of atherosclerosis within a short timeframe. Lipid-lowering therapy has to start in early childhood. Apheresis is still the treatment of choice in HoFH in whom the maximal current therapy does not achieve adequate control. Regarding the approvals of lomitapide (and mipomersen) are been obtained for adult patients, however, children with HoFH represent a particularly important group to which the indication could eventually be extended since they often develop cardiovascular heart disease in the first decade their life . In general the management of patients with rare diseases remains a continuous challenge.

Citation: Mombelli G, Castelnuovo S, Pavanello C (2014)Homozygous Familial Hypercholesterolemia “Rare Disease”. J Glycomics Lipidomics 4:e121.